Showing results (1-10 of 30) with videos related to
Sort By:
Pageof 3
Frontiers in Neuroscience|July 5, 2021
Reassessment of Pioglitazone for Alzheimer's DiseaseAnn M Saunders, Daniel K Burns, William Kirby GottschalkDrug Discovery Today|February 15, 2005
Disease-specific target selection: a critical first step down the right roadAllen D Roses, Daniel K Burns, Stephanie Chissoe, et al.Pharmacogenomics|December 15, 2010
Designing pharmacogenomic studies to be fit for purposeDaniel K Burns, Arlene R Hughes, Aidan Power, et al.Human Mutation|June 10, 2016
The SSV Evaluation System: A Tool to Prioritize Short Structural Variants for Studies of Possible Regulatory and Causal VariantsRobert Saul, Michael W Lutz, Daniel K Burns, et al.Pharmacogenomics|February 12, 2009
Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an exampleArlene R Hughes, Cynthia H Brothers, Michael Mosteller, et al.Current Neurology and Neuroscience Reports|April 5, 2016
New Genetic Approaches to AD: Lessons from APOE-TOMM40 PhylogeneticsMichael W Lutz, Donna Crenshaw, Kathleen A Welsh-Bohmer, et al.The EPMA Journal|December 3, 2010
Alzheimer's disease: diagnostics, prognostics and the road to preventionIris Grossman, Michael W Lutz, Donna G Crenshaw, et al.Current Pharmaceutical Design|November 21, 2009
Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug developmentP Anthony Akkari, Thomas W Swanson, Donna G Crenshaw, et al.Journal of Parkinson'S Disease and Alzheimer'S Disease|March 7, 2015
The Broad Impact of TOM40 on Neurodegenerative Diseases in AgingWilliam K Gottschalk, Michael W Lutz, Yu Ting He, et al.Journal of Alzheimer'S Disease : JAD|September 18, 2023
TOMM40 '523 Genotype Distinguishes Patterns of Cognitive Improvement for Executive Function in APOEɛ3 HomozygotesAmber Watts, Stephen Haneline, Kathleen A Welsh-Bohmer, et al.Pageof 3